Brief: Natera Submits Signatera™ CDx PMA To FDA
02/02/2026 11:29
Feb 2 (Reuters) - Natera Inc NTRA.O: NATERA SUBMITS SIGNATERA™ CDX PMA TO FDA NATERA INC - SUBMISSION SUPPORTED BY PHASE 3 IMVIGOR011 TRIAL DATA Source text: ID:nBwFlCBqa Further company coverage: NTRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers